Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Roivant Sciences Ltd. Director's Dealing 2025

Dec 18, 2025

30587_dirs_2025-12-17_f2af3a40-2b27-4a02-84bb-e25c805e5cbb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2025-12-15

Reporting Person: Gline Matthew (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-12-15 Common Shares M 234096 $4.06 Acquired 17521177 Direct
2025-12-15 Common Shares S 230357 $21.68 Disposed 17290820 Direct
2025-12-15 Common Shares J 3739 $21.68 Disposed 17287081 Direct
2025-12-15 Common Shares M 1363711 $12.68 Acquired 18650792 Direct
2025-12-15 Common Shares S 566116 $21.68 Disposed 18084676 Direct
2025-12-15 Common Shares J 797595 $21.68 Disposed 17287081 Direct
2025-12-15 Common Shares M 2272852 $12.68 Acquired 19559933 Direct
2025-12-15 Common Shares S 943527 $21.68 Disposed 18616406 Direct
2025-12-15 Common Shares J 1329325 $21.68 Disposed 17287081 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-12-15 Stock Option (Right to Buy) $4.06 M 234096 Disposed 2026-04-19 Common Stock (234096) Direct
2025-12-15 Stock Option (Right to Buy) $12.68 M 1363711 Disposed 2026-03-31 Common Stock (1363711) Direct
2025-12-15 Stock Option (Right to Buy) $12.68 M 2272852 Disposed 2026-03-31 Common Stock (2272852) Direct

Footnotes

F1: All options exercised by the reporting person would have expired in March or April 2026 if not exercised. The transactions reported on this Form 4 represent the disposition of the entirety of the reporting person's stock options expiring in 2026. As of the date of this filing, the reporting person has disgorged to the Issuer the full amount of the disgorgable profits realized from the sale reported herein, as required by Section 16(b) of the Securities Exchange Act of 1934.

F2: Represents the "net settlement" by the Issuer of stock options previously granted to the reporting person in order to satisfy the exercise price applicable to such stock options.

F3: Award of stock options to purchase Common Shares that is fully vested.